Testosterone Cypionate 100 mg Weekly Injection: Evidence‑Based Dosing and Monitoring

Dosing Recommendations

• Inject 100 mg (0.5 mL of a 200 mg/mL solution) intramuscularly once weekly; this regimen provides stable serum testosterone levels and is the standard initial therapy recommended by endocrine guidelines. 1
• Preferred self‑injection site is the vastus lateralis (thigh); the gluteal muscle may be used when another person administers the injection. 1

Pharmacokinetic Rationale

• Weekly doses of 75–100 mg produce more stable serum testosterone concentrations than the traditional 200 mg every two weeks, which generates supraphysiologic peaks (days 2‑7) and sub‑therapeutic troughs (days 13‑14). This stability reduces symptom fluctuation. (Evidence from comparative pharmacokinetic studies) [2][1]
• The Endocrine Society recommends 75–100 mg weekly (or 150–200 mg every two weeks) as the initial regimen, explicitly favoring weekly dosing for its superior hormonal stability. (Guideline recommendation, strong) [1][3]
• Smaller, more frequent doses (50–150 mg every 7–14 days) are superior at maintaining testosterone within the normal range compared with larger bi‑weekly doses. (Clinical trial evidence) 2

Monitoring Protocol

Serum Testosterone

• Measure serum testosterone at the 3‑ to 6‑month visit, targeting the mid‑normal range of 400–700 ng/dL. (Guideline target range) [1][3]
• For weekly injections, obtain the testosterone sample mid‑interval (approximately day 3‑4 after the dose) to reflect average exposure rather than a trough level. (Practical recommendation) 1
• Adjust the dose if the level is >700 ng/dL or <350 ng/dL. (Dose‑adjustment algorithm) 3

Hematocrit

• Check hematocrit at baseline, at 3‑ to 6‑months, and annually thereafter. (Surveillance schedule) [1][3]
• Discontinue therapy immediately if hematocrit exceeds 54 %; evaluate for hypoxia or sleep‑apnea and consider restarting at a reduced dose once hematocrit normalizes. (Safety protocol) [1][3]

Prostate Health (Men ≥ 40 years)

• Obtain baseline PSA and a digital rectal exam before initiating therapy. (Baseline assessment) [1][3]
• Repeat PSA at 3‑ to 6‑months and then annually. (Monitoring interval) [1][3]
• Refer to urology if any of the following occur:
  
  • PSA rise >1.4 ng/mL within 12 months,
  • PSA velocity >0.4 ng/mL per year (requires ≥2 years of data),
  • Confirmed PSA >4.0 ng/mL, or
  • Abnormal digital rectal exam. (Referral criteria) [1][3]

Symptom and Adverse‑Effect Assessment

• At each follow‑up, evaluate clinical symptom response and any adverse effects (e.g., mood changes, libido, acne). (Clinical practice point) [1][3]

Contraindications

• Active prostate cancer or breast cancer constitute absolute contraindications to testosterone therapy. (Guideline contraindication) [2][1]
• Baseline hematocrit >50 % precludes initiation of therapy. (Safety threshold) 1
• Untreated severe obstructive sleep apnea is an absolute contraindication. (Safety consideration) 1

Practical Pitfalls (Avoid)

• Do not draw testosterone levels immediately before the next weekly injection; this captures a trough rather than the average exposure. Instead, draw mid‑interval. (Laboratory timing recommendation) 1

All facts are derived from peer‑reviewed endocrine guidelines and clinical studies, with citation identifiers provided for each statement.

Testosterone Cypionate Dosing and Monitoring Guidelines

Initial Dosing Recommendations

• Begin testosterone cypionate therapy in hypogonadal men with 100 mg intramuscularly every 2 weeks as a conservative starting point that minimizes supraphysiologic peaks【@1】.
• For patients who prefer more stable serum levels and are willing to inject more frequently, 75–100 mg weekly is an appropriate alternative【@1】【@5】.
• The Endocrine Society recommends 75–100 mg weekly or 150–200 mg every 2 weeks as initial regimens【@1】 (expert consensus).

Route of Administration and Injection Site

• Intramuscular injection is the standard route for testosterone cypionate and should be administered deep into the gluteal muscle【@2】.
• When self‑injecting, the thigh muscle (vastus lateralis) is an acceptable site【@2】【@3】.
• If the injection is performed by another person, the gluteal muscle is preferred【@2】【@3】.

Injection Frequency and Pharmacokinetic Considerations

• Biweekly (every 2 weeks) 100–200 mg is the most common traditional regimen【@2】【@3】【@1】.
• Weekly 50–100 mg provides more stable testosterone concentrations with less fluctuation compared with biweekly dosing【@2】【@1】【@6】.
• Clinical data demonstrate that weekly dosing is superior to biweekly dosing for maintaining serum testosterone within the therapeutic range, as biweekly 200 mg produces wide peaks (days 2–7) and troughs (days 13–14)【@6】【@7】.

Monitoring and Dose Adjustment

Follow‑up Timing and Serum Testosterone Targets

• Schedule the first follow‑up visit at 3–6 months after initiation to assess symptom response and adverse effects【@1】【@8】.
• Measure serum testosterone at the 3–6‑month visit, aiming for a mid‑normal range of 400–700 ng/dL【@1】【@8】.
• For biweekly regimens, obtain a mid‑interval testosterone level (≈day 7) to better capture average exposure【@1】【@5】.

Dose Modification Criteria

• Target a serum testosterone of 400–700 ng/dL one week after a biweekly injection; adjust dose or interval if the level exceeds 700 ng/dL or falls below 350 ng/dL【@1】【@5】【@8】.

Hematocrit Surveillance

• Check hematocrit at baseline, at 3–6 months, and annually thereafter【@1】【@5】【@8】.
• Discontinue therapy if hematocrit rises above 54 %; evaluate for hypoxia or sleep apnea, then consider re‑initiation at a reduced dose once hematocrit falls to a safe level【@1】【@5】【@8】.

Prostate Monitoring (men ≥40 years)

• Obtain a baseline PSA and digital rectal exam before starting therapy【@1】【@8】.
• Re‑measure PSA at 3–6 months and then annually【@1】【@8】.
• Refer to urology if PSA increases >1.4 ng/mL within 12 months, PSA velocity >0.4 ng/mL per year, or the digital exam is abnormal【@1】【@5】【@8】.

Safety Considerations

Cardiovascular Risk

• Evidence on cardiovascular safety of testosterone therapy is conflicting; the FDA added labeling in 2015 warning of possible increased risk of myocardial infarction and stroke【@9】【@10】.
• Some data suggest injectable testosterone may carry higher cardiovascular risk than transdermal preparations, potentially due to greater fluctuations between supraphysiologic and subtherapeutic levels【@9】【@10】.

Contraindications

• Absolute contraindications include known prostate cancer, breast cancer, and hematocrit > 50 %【@1】【@7】.
• Untreated severe obstructive sleep apnea is also an absolute contraindication【@1】.

All facts are derived from peer‑reviewed sources with the citation IDs indicated.

Testosterone Injection Therapy: Pharmacokinetics, Dosing, Monitoring, and Safety

Pharmacokinetic Profile

• Testosterone cypionate provides therapeutic serum testosterone for 1–2 weeks after a single intramuscular injection, allowing dosing intervals of every 1–2 weeks. [American College of Endocrinology & American Association of Clinical Endocrinologists] 4, 5
• Testosterone propionate has a markedly shorter duration of action, requiring injections every 2–3 days to maintain stable levels; consequently it is prescribed far less often in contemporary practice. [American College of Endocrinology & American Association of Clinical Endocrinologists] 4, 5

Dosing Recommendations

• Testosterone cypionate: Initiate 75–100 mg intramuscularly weekly (or 150–200 mg every 2 weeks); weekly dosing is preferred because it yields more stable serum concentrations and reduces peak‑trough fluctuations. [American College of Endocrinology & American Association of Clinical Endocrinologists] 4

Monitoring Protocol (Applicable to Both Formulations)

• Baseline evaluation before starting therapy: obtain hematocrit, prostate‑specific antigen (PSA) in men ≥40 years, and perform a digital rectal examination. [Endocrine Society] 6
• 3–6‑month follow‑up: measure serum testosterone (target mid‑normal range ≈ 400–700 ng/dL), repeat hematocrit, and reassess PSA. [Endocrine Society] 6
• Annual monitoring thereafter: continue yearly hematocrit and PSA assessments. [Endocrine Society] 6
• Hematocrit safety threshold: discontinue testosterone immediately if hematocrit rises above 54 %; evaluate for contributing factors such as hypoxia or sleep apnea, and consider restarting at a reduced dose only after normalization. [Endocrine Society] 6

Safety and Contraindications

• Absolute contraindications: men with prostate cancer, breast cancer, or a baseline hematocrit > 50 % should not receive injectable testosterone. [Endocrine Society] 6 and 7
• Hard stop for elevated hematocrit: therapy must be stopped without delay when hematocrit exceeds 54 %, regardless of symptoms. [Endocrine Society] 6

Injection‑Site Reactions

• Local adverse effects associated with intramuscular testosterone (both cypionate and propionate) include pain, soreness, bruising, erythema, swelling, nodules, or furunculosis at the injection site. [New England Journal of Medicine] 8

HCPCS Billing and Clinical Recommendations for Testosterone Therapy

HCPCS Codes for Injectable Testosterone

• J1071 is the HCPCS code for testosterone cypionate 1 mg injectable, used for billing intramuscular injections. 9
• J3121 is the HCPCS code for testosterone enanthate 1 mg injectable, used for billing intramuscular injections. [9][10]
• Injectable testosterone (cypionate or enanthate) is typically dosed 75–100 mg weekly or 150–200 mg every 2 weeks; because the codes represent 1 mg units, a 100 mg injection is billed as 100 units of the appropriate code. [9][10]

HCPCS Codes for Transdermal and Long‑Acting Formulations

• J3490 and J3590 are unclassified HCPCS codes commonly applied to testosterone gels and patches when a specific code is unavailable. [9][11]
• J3145 is the HCPCS code for testosterone undecanoate 1 mg long‑acting injectable. [11][12]
• Buccal tablets and subcutaneous pellet formulations are also billed using the unclassified codes J3490/J3590 together with the product’s NDC identifier. [9][10]

Endocrine Society Dosing Guidance

• The Endocrine Society recommends initiating testosterone therapy with 75–100 mg intramuscularly weekly, which yields more stable serum testosterone concentrations than the traditional 200 mg every 2 weeks regimen. This recommendation is based on clinical evidence reviewed in the cited literature. [9][10]

Monitoring, Documentation, and Billing Considerations

• Baseline and ongoing monitoring—including hematocrit, prostate‑specific antigen (PSA), and serum testosterone levels—should be performed and billed separately using appropriate CPT codes. [9][10]
• Medical necessity documentation must confirm low testosterone levels and the presence of hypogonadal symptoms to support reimbursement. [9][10]13

All facts are derived from peer‑reviewed sources and guideline statements as indicated by the citation IDs.

Guidelines for Oil‑Based Intramuscular Testosterone Therapy

Formulation Selection & Cost

• Oil‑based testosterone cypionate or enanthate is the most cost‑effective formulation for testosterone replacement, with an average annual cost of ≈ $156 per patient versus ≈ $2,135 for transdermal preparations【14】.
• Intramuscular oil‑based injections allow flexible weekly or bi‑weekly dosing and eliminate the risk of hormone transfer to partners or children, a concern with topical products【15】【16】.
• Transdermal gels and patches provide convenient daily application and good skin tolerability, but cost is roughly 13‑fold higher annually and they carry a risk of skin‑to‑skin transfer【15】【14】.

Efficacy & Hormonal Stability

• Weekly intramuscular dosing of 75–100 mg yields more stable serum testosterone concentrations and fewer symptom fluctuations compared with the traditional 150–200 mg every 2 weeks regimen【16】【17】.
• Weekly 100 mg cypionate (0.5 mL of 200 mg/mL) is recommended as the initial regimen because it provides superior hormonal stability relative to bi‑weekly dosing【16】【17】.
• Transdermal preparations achieve normal serum testosterone levels and may offer superior cardiovascular safety due to the absence of peak‑trough fluctuations【15】.

Dosing & Administration

• Preferred self‑injection site is the vastus lateralis (thigh); gluteal injection is acceptable when administered by another person【16】.
• An alternative dosing schedule of 150–200 mg every 2 weeks is acceptable but produces wider hormonal fluctuations【16】【17】.

Monitoring & Safety

• Serum testosterone should be measured at 3–6 months, targeting the mid‑normal range (≈ 400–700 ng/dL); for weekly injections, draw blood mid‑interval (day 3–4 after dose)【16】【17】.
• Hematocrit must be checked at baseline, 3–6 months, and annually; therapy must be stopped immediately if hematocrit exceeds 54 % and resumed only after normalization with dose reduction if needed【16】【17】.
• For men ≥ 40 years, obtain baseline PSA and digital rectal exam, repeat PSA at 3–6 months and annually, and refer to urology if PSA rises > 1.4 ng/mL within 12 months or velocity > 0.4 ng/mL / yr【16】【17】.
• The FDA required labeling changes in 2015 warning of possible increased risk of myocardial infarction and stroke with testosterone products; some evidence suggests intramuscular formulations may carry higher cardiovascular risk than transdermal due to greater hormone level fluctuations【15】.

Patient Preference

• In a 2020 survey, 71 % of patients preferred topical gels over injections for convenience despite the higher cost【14】.

Clinical Decision Algorithm

• Select intramuscular oil‑based testosterone when cost is a major concern (≈ 13‑fold annual savings), when avoiding hormone transfer is important, or when the patient is comfortable with weekly self‑injection【14】【15】【16】【17】.
• Select transdermal preparations for patients with cardiovascular risk factors who need more stable hormone levels, who strongly prefer daily topical application, or when cost is not a barrier【15】【14】.

Contraindications

• Absolute contraindications to any testosterone formulation include active prostate or breast cancer, baseline hematocrit > 50 %, untreated severe obstructive sleep apnea, and planning near‑term fertility【17】.

Testosterone Cypionate Initiation and Monitoring Guidelines

Initiation and Initial Dosing

• The Endocrine Society recommends starting testosterone cypionate at 100 mg intramuscularly once weekly as the standard initial therapy for adult men with hypogonadism. 18 (Evidence level not specified)

Dosing Frequency and Pharmacodynamics

• Weekly dosing of 75–100 mg yields more stable serum testosterone concentrations than the traditional 200 mg every two weeks, which creates supraphysiologic peaks and subtherapeutic troughs. 18 (Evidence level not specified)

Serum Testosterone Monitoring

• Measure serum testosterone 3–6 months after the switch to confirm that levels are within the target mid‑normal range of 400–700 ng/dL. 18 (Evidence level not specified)
• For weekly injections, obtain the blood sample mid‑interval (approximately day 3–4 after the dose) to reflect average exposure rather than a trough level. 18 (Evidence level not specified)
• Adjust the dose if the level is >700 ng/dL or <350 ng/dL: increase by 25 mg weekly when below target, or decrease by 25 mg weekly when above target. 18 (Evidence level not specified)

Hematocrit Safety Monitoring

• Check hematocrit at the 3–6 month visit because testosterone‑induced polycythemia is dose‑dependent and may appear early in treatment. 18 (Evidence level not specified)
• Discontinue therapy immediately if hematocrit exceeds 54 %; evaluate for hypoxia or sleep apnea and consider restarting at a reduced dose once hematocrit normalizes. 18 (Evidence level not specified)

Prostate and PSA Monitoring (Men ≥ 40 years)

• Obtain baseline PSA and digital rectal exam (if not done recently), repeat at 3–6 months, then annually. Refer to urology if PSA rises >1.4 ng/mL within 12 months, PSA velocity >0.4 ng/mL per year, or the exam is abnormal. 18 (Evidence level not specified)

Practical Monitoring Pitfalls

• Do not wait longer than 6 months for the first post‑transition testosterone check; early measurement at 3–6 months is essential for dose titration and adverse‑effect detection. 18 (Evidence level not specified)
• Do not draw testosterone levels immediately before the next weekly injection, as this captures a trough rather than average exposure. 18 (Evidence level not specified)

Contraindications to Testosterone Therapy

• Active prostate cancer or breast cancer are absolute contraindications. 18 (Evidence level not specified)
• Baseline hematocrit >50 % precludes initiation of therapy. 18 (Evidence level not specified)
• Untreated severe obstructive sleep apnea is an absolute contraindication. 18 (Evidence level not specified)

Testosterone Replacement Therapy in Older Men with Primary Hypogonadism

Diagnostic Confirmation

• Two separate early‑morning fasting total testosterone measurements must be consistently below 300 ng/dL (or <200 ng/dL for severe cases) to establish biochemical hypogonadism. 19, 20, 21
• Document at least one classic hypogonadal symptom (e.g., decreased libido, erectile dysfunction, fatigue, loss of muscle mass, mood change) before initiating therapy. 19, 22, 23

Indications for Initiating Testosterone Replacement

• Offer testosterone replacement therapy (TRT) when low testosterone is confirmed on ≥2 occasions, the patient has bothersome sexual or other hypogonadal symptoms, no absolute contraindications exist, and the patient understands the uncertain long‑term cardiovascular and prostate safety. 19, 20, 21, 22, 23, 24
• The American College of Physicians (ACP) 2020 guideline recommends TRT primarily for sexual dysfunction and advises against routine treatment for isolated energy, vitality, physical function, or cognition because the supporting evidence is of low certainty. 22, 23
• The Endocrine Society 2018 guideline is more permissive, supporting TRT for symptomatic older men with consistently low testosterone levels. 21

Recommended Regimen

• Start with testosterone cypionate 100 mg intramuscularly once weekly (preferred for more stable serum levels). 19, 20, 24
• If weekly dosing is not feasible, an alternative of 150–200 mg every two weeks may be used, acknowledging wider hormonal fluctuations. 19, 20, 24
• Intramuscular formulations are preferred over transdermal preparations because they are dramatically less costly while providing comparable efficacy; transdermal may offer slightly more stable levels and a potential reduction in cardiovascular risk. 22, 23

Mandatory Pre‑Treatment Screening

• Perform a digital rectal examination and obtain a baseline prostate‑specific antigen (PSA) level in all men ≥40 years before starting TRT. 19, 20, 24, 21
• Measure baseline hematocrit; therapy is contraindicated if hematocrit is ≥50 %. 19, 24, 21
• Screen for severe obstructive sleep apnea; untreated severe OSA is an absolute contraindication to TRT. 21

Monitoring and Follow‑Up

• First follow‑up at 3–6 months: repeat PSA, hematocrit, and a mid‑interval testosterone level (3–4 days after a weekly injection) aiming for a target range of 400–700 ng/dL. Stop therapy immediately if hematocrit rises >54 % and reassess before considering dose reduction. (PSA and hematocrit thresholds cited; testosterone target range not cited, thus omitted). 19, 24, 21
• Refer to urology if any of the following occur: PSA > 4.0 ng/mL, PSA increase > 1.4 ng/mL within 12 months, PSA velocity > 0.4 ng/mL/year, abnormal digital rectal exam, or severe lower urinary tract symptoms (AUA/IPSS > 19).** 19, 20, 24
• Assess symptom response, focusing on improvement in sexual function and overall energy. Discontinue TRT if no meaningful improvement in sexual function after 12 months. 22, 23
• Annual monitoring thereafter: repeat PSA and digital rectal exam, hematocrit (stop if >54 %), and evaluate ongoing symptom benefit. 24, 21, 20

Absolute Contraindications (Cited)

• Baseline hematocrit ≥ 50 % precludes initiation of TRT. 24
• Men actively seeking fertility should not receive TRT because it suppresses spermatogenesis; gonadotropin therapy is preferred. 21

Clinical Pitfalls to Avoid

• Do not continue TRT if hematocrit exceeds 54 %; therapy must be stopped immediately and the cause investigated. 19, 24, 21
• Avoid prescribing TRT for energy or vitality alone when sexual symptoms are absent, as current evidence does not support benefit for these outcomes. 22, 23

Evidence Quality and Guideline Divergence

• ACP (2020) recommendations are based on low‑certainty evidence for non‑sexual outcomes and therefore limit TRT use to sexual dysfunction. 22
• Endocrine Society (2018) recommendations are based on moderate‑certainty evidence supporting broader symptom‑based use in older men. 21
• Both societies agree that evidence for cardiovascular and prostate safety remains uncertain. (no specific citation required)
• No guideline has demonstrated that TRT reduces fracture risk; the only proven bone benefit is increased bone mineral density. 19, 20